Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia. - Wikidata - wikimedia - TriplyDB

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

http://www.wikidata.org/entity/Q40705613

about

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies Burkitt lymphoma in adolescents and young adults: management challenges.Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.New Therapeutic Strategies in Acute Lymphocytic Leukemia.Immunotherapy in hematologic malignancies: past, present, and future.Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Antibodies to watch in 2017 Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.Recent developments in immunotherapy of acute myeloid leukemia.Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Gemtuzumab ozogamicin in acute myeloid leukemia.Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.New Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat It.Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?Antibody-Based Treatment of Acute Myeloid Leukemia.Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.Emerging biological therapies to treat acute lymphoblastic leukemia.The combination of bortezomib with chemotherapy to treat relapsed/refractory acute lymphoblastic leukaemia of childhood.Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.Viewing Siglecs through the lens of tumor immunology.Acute lymphoblastic leukemia in adolescents and young adults.Treatment of Young Adults with Acute Lymphoblastic Leukemia.Philadelphia-Like Acute Lymphoblastic Leukemia in Adults.Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.Continuing challenges and current issues in acute lymphoblastic leukemia.Novel therapy for childhood acute lymphoblastic leukemia.Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.Acute lymphoblastic leukemia: a comprehensive review and 2017 update Advances in adult acute lymphoblastic leukemia therapy.Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins.Syk inhibitors in clinical development for hematological malignancies.

P2860

Q28072131-CDC201E4-FC21-4CA4-8905-9889E9F7DC24 Q30238965-C29DA5C0-E9BB-4B19-9826-A317D36F2DF5 Q30240892-3B86E671-7BBD-4B21-AC57-4A84F6E80A7C Q30252776-09786324-80DC-4CE7-BF91-63BC178F9F71 Q33593865-F09AA1D6-1B86-44A0-8192-1D276006A071 Q33742940-0E9F784A-37B9-46CE-A407-5D53E6F99218 Q37517482-2320F076-E683-47DD-8A29-3DDBBBC6E5F8 Q37631319-3114DC78-EA9E-4BF7-84DD-609AF3626374 Q38371346-B35F459C-006E-42FA-A854-6CCE0AFA7789 Q38639698-C96E5FC6-0CFD-4676-984A-5979B8AE1934 Q38640263-C3A095AC-E312-4157-BD34-74BC9E90D306 Q38646986-F8F42385-8262-4137-B78B-DB79ADE9DC04 Q38661895-F1937DC5-0045-4D3F-AF22-287A0AD15330 Q38666159-06EDA4FD-931E-489A-AB42-B9950949E6B8 Q38728718-E53F20E4-689E-4633-A039-63EDA5430A82 Q38734309-E1AB3EDE-7874-4721-A6F7-3E30DDA42A21 Q38752449-946A3B93-2ADC-448C-A1F1-BAB220BD3376 Q38756821-05A43196-F59E-4A2E-B7D2-163F9319316A Q38818973-5BEE59FE-22D8-4EE6-8E96-89831AC871E9 Q38953608-F7ED791C-AA73-4C8D-B6E4-1EFB2B2A7EB3 Q38979277-F1A24991-9DAF-4C3D-A079-4D0511976757 Q38984055-F75C2F1B-A402-4332-87F1-4E43057A52BD Q39002036-63585C3C-E6EC-4F05-BB8B-D73D9E20812B Q39002810-FB1F8392-AE97-403B-8746-7383F1DC17E2 Q39041475-3E13A05D-738B-4118-B623-2A9F0321FAA4 Q39059681-94300EC8-1880-4D62-B588-2DE3B4726435 Q39160967-6D13D17C-7A26-45C7-8EB7-F94D09679EC5 Q39192991-5F86C828-CCE9-4EF0-A8DB-75611E3067DD Q39206217-763C1D5C-01A0-4859-8F0E-891BF51F9C59 Q39210250-4BEC3644-6A0B-4D26-84AD-BCBAC822AA4C Q39210427-4DCD2823-B6B4-4589-9EDF-18E31BF89B0B Q39243052-57E4B9F5-1A00-4F94-B80F-55E0EDD30187 Q39366299-CB917813-7271-41A1-835E-F652AF885AC2 Q39368957-651F9F83-4807-4596-9E54-D604D97F6941 Q39401736-00F3EE69-82AA-443F-81B1-4B109843FC36 Q39406969-37E80750-A6A6-4CC0-8D39-62E27B9AA7FB Q39459190-ECEB099D-FCD7-410D-9EFD-B048AC1D1A89 Q40312849-29C1C2F7-467F-42AC-A8AB-89ECF95268E1 Q41207923-1F954D80-E06A-41B2-A244-C0FD2FC7698E Q42011012-C8495654-4206-429F-8575-87D8C81AB43E

P2860

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

http://www.wikidata.org/entity/Q40705613

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

@en

type

label

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

@en

prefLabel

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

@en

P1433

Q40705613-C1FB4853-28FB-4FFB-807E-558FB5A91237

P1476

Q40705613-F707ED3C-0CAB-43C0-B633-F67F6519F930

P2093

Q40705613-0E818C59-088B-40A2-974F-5D1E44E61107

Q40705613-1A08EC1C-D7E1-480A-AFF5-4C6009474DEC

Q40705613-30662324-D61B-4FC3-9D13-F440EE92F0D3

Q40705613-367F42D3-001C-4110-A09E-725A5E57A08E

Q40705613-58A1F477-A002-4DEF-AFCE-AA4EF9C3D330

Q40705613-7688E83E-4CEA-4B1B-B7C4-EA788565E6E0

Q40705613-88DE63E3-3A52-4CDB-BCE1-8435A957A030

Q40705613-92042D02-E6AF-41CC-8C1D-FE4EBED47437

Q40705613-93C29E5C-5B98-4176-81BE-9DE435C87479

Q40705613-BE7BBA36-1961-44C6-8330-7C69F5ABAC32

P2860

Q40705613-1CD5985B-1BBA-4473-9FAE-12F499779C7E

Q40705613-1D18EDDC-EEBF-46DA-BF96-7BDB0EFB59AE

Q40705613-31C0C0BA-C54D-4999-BDD8-2F583E4B6AF4

Q40705613-327CFF2D-668A-4687-868F-4F34F7290E4F

Q40705613-440E4DAF-F204-4752-923B-DA3B583F13C1

Q40705613-48067405-BFE5-469D-BB0B-0EE3D34FB795

Q40705613-52C17FE2-17D1-49B0-8C5C-A33648810008

Q40705613-5D497F8F-5A02-448C-8ACB-460274DE148E

Q40705613-5DDF33E4-27EF-46A5-8AAD-27A3F41332FA

Q40705613-633C68DF-95F5-4125-850B-9200C173F95D

P304

Q40705613-61CEFFEA-64FC-46D5-BB34-A312DE5F6315

P31

Q40705613-BABE636E-AFFB-4271-9070-B60A98AF490F

P356

Q40705613-3DA2AE61-FBAB-4E86-B68F-B4E14DF516D7

P407

Q40705613-3E355693-73A8-4676-9DC9-1868BA95A802

P433

Q40705613-70B4A01C-1B12-4029-A6E5-C1351354B4E7

P478

Q40705613-159AECB0-879C-4C37-B3D2-70A03148F41A

P50

Q40705613-5C01CD1D-1026-469E-8955-12B5A58D5CAF

Q40705613-CA4488DE-FE28-4BC3-A405-FC6927ABAA7B

Q40705613-D0A2DE46-3FE2-4703-9852-EBA30D045241

Q40705613-F3B2FFDC-3975-4F2A-B515-C2F5FF80456D

P577

Q40705613-8642B582-83E7-4D7F-8251-DFC1201D4F2F

P698

Q40705613-DAA85FB5-B97F-4457-AD2D-D8B3AF5AA8B6

P921

Q40705613-CABB11B6-4978-42C7-8198-24A99C859C57

P932

Q40705613-67E16DA7-CDE8-48DD-96E1-4C0A128142BC

P356

P1433

The New England Journal of Medicine

P1476

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.

@en

P2093

Anjali S Advani

http://www.w3.org/2001/XMLSchema#string

Barbara Sleight

http://www.w3.org/2001/XMLSchema#string

Daniel J DeAngelo

http://www.w3.org/2001/XMLSchema#string

Erik Vandendries

http://www.w3.org/2001/XMLSchema#string

Kongming Wang

http://www.w3.org/2001/XMLSchema#string

M Luisa Paccagnella

http://www.w3.org/2001/XMLSchema#string

Matthias Stelljes

http://www.w3.org/2001/XMLSchema#string

Michaela Liedtke

http://www.w3.org/2001/XMLSchema#string

Nicola Gökbuget

http://www.w3.org/2001/XMLSchema#string

Tao Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Monoclonal antibodies in acute lymphoblastic leukemia

Cancer statistics, 2015

Chimeric antigen receptor T cells for sustained remissions in leukemia

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study.

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Characterization of CD22 expression in acute lymphoblastic leukemia

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

P304

740-753

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1509277

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Nicola Gökbuget

Hagop Kantarjian

Giovanni Martinelli

P577

2016-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27292104

http://www.w3.org/2001/XMLSchema#string

P921

P932

5594743

http://www.w3.org/2001/XMLSchema#string